(Q53386775)

English

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

Alzheimer's disease

0 references

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

G Lefèvre

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

G Sedek

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

S S Jhee

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

M T Leibowitz

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

H-La Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

A Enz

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

S Maton

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

L Ereshefsky

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

F Pommier

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

H Schmidli

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

S Appel-Dingemanse

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

language of work or name

0 references

publication date

23 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

83

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

106-114

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Inhibition of human cholinesterases by drugs used to treat Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

A new and rapid colorimetric determination of acetylcholinesterase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Confidence interval criteria for assessment of dose proportionality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

21 January 2018

Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100242

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CLPT.6100242

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/17522596

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53386775&oldid=2143947500"